ALFA Finder| Revenue growth | Consolidated Q4 revenue up 22%; full year FY26 up 7%. |
|---|---|
| Margins | Improvement supported by favorable product mix and operational discipline. |
| Order book | Supplied 6.3 crore PPR doses in Q4 under national program. |
| Demand visibility | Strong for biologicals; Animal Health recovery expected following tender delays. |
| Management confidence | Confident in long-term results from consolidation and capacity expansion initiatives. |
Growth
Q4 revenue grew 22%; Standalone PAT up 174%. FY26 consolidated revenue rose 7%, PAT nearly doubled.
Outlook
Focus on 50-50 revenue mix between Poultry and Animal Health; ramp-up of BSL-3 and Fill-Finish facilities.
Risks
Tender-led business timing volatility, rising raw material costs, and geopolitical supply chain disruptions.
Earnings Call filed with BSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,341.30
- Market cap
- ₹1,992 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 14.0×Sector 43.8×
- Promoter holding
- 44.28%-9.45% QoQ
- FII holding
- 0.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Investor Presentation: Key Takeaways
Standalone revenue +28% Q2, +21% H1; PAT +131% Q2. EBITDA margin 35%, gross margin 78%. H1 consolidated PAT boosted by one-time Africa loan gain.
Hester Biosciences Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 44.1% YoY
Hester Biosciences Ltd reported revenue from operations of ₹97.9 Cr (+37.9% YoY) and net profit of ₹20.6 Cr (+44.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.6 Cr · +44.1% YoY
Hester Biosciences Board Meeting Date
Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.
Hester Biosciences Management Change
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences Other Announcement
Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.
Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
- Value
- ₹1.05 Cr
- Execution
- six months